Recovery Stack: BPC-157 + TB-500 + GHK-Cu Research Protocol
The BPC-157 + TB-500 + GHK-Cu recovery stack combines three mechanistically distinct repair pathways: growth factor/NO signalling (BPC-157), actin dynamics and cell migration (TB-500), and collagen synthesis/gene regulation (GHK-Cu). Together they address the full repair cascade — from angiogenesis through cellular recruitment to ECM remodelling.
Full 2³ factorial: each of the 8 combinations (vehicle, BPC-157 alone, TB-500 alone, GHK-Cu alone, all two-way combinations, and full triple stack) in wound healing model. Identifies independent and interaction effects. 8-arm study with n=6/group.
Why this combination?
BPC-157 initiates repair via growth factor signalling — VEGF drives angiogenesis, EGF receptor activation drives fibroblast proliferation, NO/eNOS supports vascular tone. TB-500 provides the cellular migration substrate — free G-actin (released by Tβ4 sequestration) enables keratinocytes, myoblasts, and endothelial cells to migrate into the wound site. GHK-Cu then promotes ECM remodelling — stimulating collagen I and III synthesis while regulating MMPs to prevent excessive fibrosis. The three compounds address sequential phases of repair.
❓
Frequently Asked Questions
Why add GHK-Cu to BPC-157 and TB-500?
BPC-157 and TB-500 primarily address the early repair phases: angiogenesis, inflammation resolution, and cellular migration. GHK-Cu addresses the later ECM remodelling phase — collagen synthesis, MMP/TIMP regulation, and prevention of fibrosis. Without collagen remodelling, early repair may produce scar rather than functional tissue restoration.
What is the right dosing for the three compounds in this stack?
Based on published animal model data: BPC-157 10-15 µg/kg SC daily, TB-500 2 mg/kg SC 2-3x/week, GHK-Cu 1-2 mg/kg SC daily. QSC supplies all three separately and as a pre-combined BPC-157+TB-500 blend for convenience. See the reconstitution calculator for mixing guidance.
Can all three compounds be combined in one injection?
Compatibility research is limited. The more common approach in research is separate injections to avoid potential pH or stability interactions. The BPC-157+TB-500 pre-blend is an exception — these two are typically combined in research. GHK-Cu is typically administered separately.
